Evaluating the results of the Momguard noninvasive prenatal test

from an NT ultrasound and maternal serum tests has been used for noninvasive prenatal test (NIPT) [4]. If a test result indicates a sample is ‘screen positive’, chorionic villus sampling (CVS) or amniocentesis is performed to confirm the result. However, current maternal serum screening tests have a relatively low detection rate (50-95%) and high false-positive rate (5%) [5]. CVS and amniocentesis carry the risk of fetal loss, since they are invasive procedures and may present additional emotional burdens for the mother. The discovery of the existence of cell-free fetal DNA (cffDNA) in maternal plasma in 1997 by Lo et al. [6] led to a new era for NIPT. Within the last two decades, advanced technologies such as digital polymerase chain reaction or massively parallel Evaluating the results of the Momguard noninvasive prenatal test